Clinical data: Contact history, symptomatology, comorbidities, hospitalization & treatment history, clinical outcomes


Blood (10 mL)

Blood (25 mL) (Serum, PBMCs)

Naso-/
oropharyng
eal swab

**Supplemental Figure 1.** Study flow of the cohort. The follow up presented here is up to 6-10 weeks.

**Supplemental Figure 2.** Comparison of RT-PCR threshold values (CT) between asymptomatic and symptomatic participants among seroconverters and non-seroconverters (N=169).



False: Non seroconverters; True: Seroconverters. Statistical test applied between asymptomatic and symptomatic groups: Mann Whitney test; among seroconverters: p-value 0.48 and among non seroconverters: *P*-value 0.16.

## Supplemental Table S1. Patterns of seropositivity across the three timewindows of illness

Within 7 days	10-28 days	6-10 weeks	Anti-RBD	Anti-NC assay
of onset of			assay [n (%)]	[n (%)]
illness*			N=743	N=673
Negative	Negative	Negative	99 (13.3)	120 (17.8%)
Negative	Negative	Positive	21 (2.8)	39 (5.8%)
Negative	Positive	Negative	7 (1.0)	12 (1.8%)
Negative	Positive	Positive	305 (40.9)	269 (40.0%)
Positive	Negative	Negative	2 (0.3)	1
Positive	Negative	Positive	1 (0.1)	0
Positive	Positive	Negative	2 (0.3)	12 (1.9%)
Positive	Positive	Positive	309 (41.4)	220 (33.7%)

<sup>\*</sup> From the onset of symptoms in case of symptomatic or date of testing for asymptomatic participants.

Anti-NC and anti-RBD IgG denote anti-nucleocapsid and anti-RBD Immunoglobulin-G respectively.